Gilbert M T, Barinov-Colligon I, Miksic J R
Rhône-Poulenc Rorer, Collegeville, PA 19426, USA.
J Pharm Biomed Anal. 1995 Apr;13(4-5):385-94. doi: 10.1016/0731-7085(95)01310-h.
Increased reliance on pharmacokinetic studies in regulatory submissions emphasizes the need for cross-validating bioanalytical methods between different laboratories to allow comparison of data. Globalization of pharmaceutical development results in a greater need to define cross-validation standards. A strategy for performing cross-validation experiments using prepared biological samples of known concentration and "real" samples from clinical trials is presented. The statistical techniques used to compare data sets and establish acceptability of the assays are illustrated by practical examples.
在监管申报中对药代动力学研究的依赖增加,凸显了在不同实验室之间对生物分析方法进行交叉验证以实现数据比较的必要性。药物研发的全球化导致对定义交叉验证标准的需求更大。本文介绍了一种使用已知浓度的制备生物样品和来自临床试验的“真实”样品进行交叉验证实验的策略。通过实际例子说明了用于比较数据集和确定分析方法可接受性的统计技术。